Novocure Limited (NVCR)
|Net Income (ttm)||-4.57M|
|Day's Range||126.86 - 131.00|
|52-Week Range||103.00 - 232.76|
|Price Target||177.14 (+39.2%)|
|Est. Earnings Date||Oct 28, 2021|
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and int... [Read more...]
Financial PerformanceFinancial Statements
According to 9 analysts, the average rating for Novocure stock is "Hold." The 12-month stock price forecast is 177.14, which is an increase of 39.15% from the latest price.
Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating Fields (TTFields) together with Roche's atezolizumab i...
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combi...
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #pancreaticcancer--Novocure has entered into a clinical trial collaboration with Roche to evaluate TTFields as part of a novel combination to treat pancreat...
Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--The U.S. FDA has granted breakthrough device designation to Novocure's NovoTTF-200T™ System for advanced liver cancer.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021.
The company has several key data readouts on the way.
Uptake of the company's revolutionary disease-controlling device isn't progressing as quickly as expected.
Investors are seeing red in the company's latest earnings report.
NovoCure (NVCR) delivered earnings and revenue surprises of -800.00% and -5.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Novocure Ltd (NASDAQ: NVCR) posted a net loss of $14.6 million in Q2, compared to a net income of $1.7 million a year ago. EPS came in at $(0.14), missing the consensus of $0.01 Q2 net revenues were $13...
Shares of NovoCure (NASDAQ:NVCR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were down 800.00% over the past year to ($0.14), which missed the estimat...
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure reported financial results for the second quarter 2021, highlighting commercial strength and strategic investment.
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the second quarter 2021 on July 29, 2021, before the U.S. financial markets open.
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Novocure Ltd (NASDAQ: NVCR) has announced final results from its phase 2 pilot HEPANOVA trial evaluating Tumor Treating Fields (TTFields) together with Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) for he...
Investors hoped for better results from the company's phase 2 study.
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
ST. HELIER, Jersey--(BUSINESS WIRE)-- #patientforward--Novocure announced final safety and efficacy results from its HEPANOVA trial in liver cancer, and plans to proceed with a phase 3 pivotal trial.
NovoCure's unique treatment for cancerous tumors is both a medical breakthrough and an investment opportunity.
Investors who can pinpoint the overhyped toxic stocks and discard them at the right time are the ones who are poised to benefit.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced it has advanced a new, flexible torso array into a clinical usability study.
These fundamentally strong stocks are much better bets than the over-hyped Dogecoin.